Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up
NCT ID: NCT03487900
Last Updated: 2022-08-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
320 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-03-13
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The CREDO 2 study follows CREDO 1 study, which aims to construct an objective evaluation of endoscopic remission in Crohn's Disease (CD). In addition to reproducibility and validation, the predictive value of this remission evaluation needs to be tested in different settings to valorise its usefulness in clinical practice and in clinical trials.
CREDO 2 aims to investigate whether the evaluation of endoscopic remission, as defined in CREDO 1, in patients in clinical remission is predictive of sustained clinical remission at 2 years.
The design of CREDO2 is a multicentre longitudinal prospective cohort study. The screening period to include a patient is two weeks. Patients will be followed up to week 104.
CREDO 2 aims to investigate whether the evaluation of endoscopic remission, as defined in CREDO 1, in patients in clinical remission is predictive of sustained clinical remission at 2 years.
The design of CREDO2 is a multicentre longitudinal prospective cohort study. The screening period to include a patient is two weeks. Patients will be followed up to week 104.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Crohn's Disease Endoscopic REmission Definition in an Objective Way
NCT03498625
CD
COMPLETED
NA
Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin
NCT06972901
Crohn Disease (CD)
Ileocolic Resection
Post-endoscopic Operative Reccurence
RECRUITING
NA
CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease
NCT01183403
Crohn's Disease
COMPLETED
Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
NCT02826330
Crohn's Disease
Genetic Predisposition
COMPLETED
Prediction and Close Monitoring of Postoperative Recurrence by Intestinal Ultrasound After Ileocecal Resection in Crohn's Disease Patients
NCT05713409
Crohn Disease
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The CREDO 2 study follows CREDO 1 study, which aims to construct an objective evaluation of endoscopic remission in Crohn's Disease (CD). In addition to reproducibility and validation, the predictive value of this remission evaluation needs to be tested in different settings to valorise its usefulness in clinical practice and in clinical trials.
CREDO 2 aims to investigate whether the evaluation of endoscopic remission, as defined in CREDO 1, in patients in clinical remission is predictive of sustained clinical remission at 2 years. The design of CREDO2 is a multicentre longitudinal prospective cohort study. The screening period to include a patient is two weeks. Patients will be followed up to week 104. The primary endpoint is sustained clinical remission at week 104. The primary secondary endpoints are sustained clinical remission at weeks 26 and 52. The sustained clinical remission at 2 years is defined by the absence of relapse and complication of the disease. Relapse is defined as Crohn's Disease Activity Index (CDAI) \> 220 or between 150 and 220 for 2 consecutive weeks with an increase of at least 70 points relative to the baseline CDAI, associated with an objective marker of inflammation: C-reactive protein (CRP) ≥5 mg/l and / or faecal calprotectin ≥250 μg/g. CD complication is defined by an intestinal resection surgery for CD, stricturoplasty, endoscopic dilatation, hospitalisation for intestinal strictures, abscess and / or fistula (including anoperineal disease) and/or therapeutic escalation. Therapeutic escalation is defined as an increase in the dosage of the treatment, shortening of the treatment interval, addition of a new treatment for CD (including corticosteroids, immunosuppressants, biologics, Janus kinase (JAK) inhibitors or any experimental treatment). The number of patients to be included is 320 when using a two-sided test with a type 1 error of 5% to detect with a power of 80% an association between a predictor and week 104 sustained remission failure, corresponding to a variation in proportions of patients who failed from 40% in the high-risk group to 20% in the low-risk group, and assuming a 12% loss due to treatment discontinuation or patient withdrawal. Patients will be recruited via two cohorts. First, patients included in CREDO 1 could be included in CREDO 2 if they agree and meet the criteria of non-exclusion. Assuming that 2/3 of the 15 patients included in each of the 16 centres involved in CREDO 1 could be included in CREDO 2, 160 patients will be included from CREDO 1. An additional cohort of 10 patients per centre will be included in CREDO 2 by the same local investigator within each centre using the same methods as for CREDO 1 cohort, except that recruitment criteria will be those of CREDO 2, to provide 160 additional patients to reach the targeted cohort size for CREDO 2. Recruitment will therefore be performed in 16 centres and each local investigator will have to register 20 videos, including those selected from CREDO 1, stratified by endoscopic remission status according to his/her global judgment: complete remission; almost complete remission; neither complete nor almost complete remission. The main inclusion criteria are adult patients, with established CD with ileal and / or colonic involvement, without significant clinical activity for more than 3 consecutive months with, at baseline, CDAI \<150 and CRP \<5 mg / l and faecal calprotectin \<250 μg / g, stable maintenance treatment for more than 3 months, an ileocolonoscopy planned for CD and the decision to maintain or decrease the treatment (but not increase) after the colonoscopy. All maintenance treatments are authorized / immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), biologic (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, vedolizumab) and JAK inhibitors.The main exclusion criteria are an incomplete record of the ileocolonoscopy or more than three resected ileocolonic segments (not counting ileocecal valve), taking NSAIDs in the two weeks prior to endoscopy, anoperineal MC without luminal involvement, suspicion of intestinal infection within 4 weeks prior to baseline endoscopic assessment. The expected period of recruitment is 12 months from the first patient included in the study and 20 patients will be included in each of the 16 centres in Belgium and France. At inclusion, demographic, phenotypic, medical history and treatment data will be collected and ileocolonoscopy will be performed and recorded by the local investigator using pre-specified standards, provided sufficient quality. Biological (albumin, haemoglobin, platelets, CRP and faecal calprotectin) assessments will be carried out at the inclusion and at each follow-up visit (week 26, 52 104 and unplanned). The clinical activity will be evaluated through CDAI. Within each centre, the local investigator, as local reader, will read the 20 ileocolonoscopy videos of the centre. In addition, each video will be read by central readers, selected among 12 central readers in four groups of 3 central readers. Each video will be read by 2 central readers and by a third one in case of disagreement between the first two. Each central reader will read a little more than 54 videos due to these disagreements. All these readers, local and central, will have undergone the training session validated by an examination on the evaluation of endoscopic remission. In a separate delayed session, the central readers will evaluate components of usual endoscopic severity indices. Agreement between data provided by local readers and central readers will be assessed through Kappa and intraclass correlation coefficient estimates. If agreement is satisfactory, endoscopic data provided by local readers will be used to investigate the association between baseline endoscopic evaluation and sustained clinical remission at week 104 using the logistic regression method, ROC curves, sensitivity and specificity. If agreement is poor, the association will be studied on central reader data using the same methods.
This study should provide a tool to evaluate the ability of endoscopic remission evaluation in patients in clinical remission to accurately predict sustained clinical remission. If it is the case, this tool could become the therapeutic objective for patients in clinical remission with ileal and/or colonic CD. If agreement is satisfactory between local and central reading, the tool could be used in therapeutic trials, but also in clinical practice. If this is not the case, the tool should be used in clinical trials using central readings.
CREDO 2 aims to investigate whether the evaluation of endoscopic remission, as defined in CREDO 1, in patients in clinical remission is predictive of sustained clinical remission at 2 years. The design of CREDO2 is a multicentre longitudinal prospective cohort study. The screening period to include a patient is two weeks. Patients will be followed up to week 104. The primary endpoint is sustained clinical remission at week 104. The primary secondary endpoints are sustained clinical remission at weeks 26 and 52. The sustained clinical remission at 2 years is defined by the absence of relapse and complication of the disease. Relapse is defined as Crohn's Disease Activity Index (CDAI) \> 220 or between 150 and 220 for 2 consecutive weeks with an increase of at least 70 points relative to the baseline CDAI, associated with an objective marker of inflammation: C-reactive protein (CRP) ≥5 mg/l and / or faecal calprotectin ≥250 μg/g. CD complication is defined by an intestinal resection surgery for CD, stricturoplasty, endoscopic dilatation, hospitalisation for intestinal strictures, abscess and / or fistula (including anoperineal disease) and/or therapeutic escalation. Therapeutic escalation is defined as an increase in the dosage of the treatment, shortening of the treatment interval, addition of a new treatment for CD (including corticosteroids, immunosuppressants, biologics, Janus kinase (JAK) inhibitors or any experimental treatment). The number of patients to be included is 320 when using a two-sided test with a type 1 error of 5% to detect with a power of 80% an association between a predictor and week 104 sustained remission failure, corresponding to a variation in proportions of patients who failed from 40% in the high-risk group to 20% in the low-risk group, and assuming a 12% loss due to treatment discontinuation or patient withdrawal. Patients will be recruited via two cohorts. First, patients included in CREDO 1 could be included in CREDO 2 if they agree and meet the criteria of non-exclusion. Assuming that 2/3 of the 15 patients included in each of the 16 centres involved in CREDO 1 could be included in CREDO 2, 160 patients will be included from CREDO 1. An additional cohort of 10 patients per centre will be included in CREDO 2 by the same local investigator within each centre using the same methods as for CREDO 1 cohort, except that recruitment criteria will be those of CREDO 2, to provide 160 additional patients to reach the targeted cohort size for CREDO 2. Recruitment will therefore be performed in 16 centres and each local investigator will have to register 20 videos, including those selected from CREDO 1, stratified by endoscopic remission status according to his/her global judgment: complete remission; almost complete remission; neither complete nor almost complete remission. The main inclusion criteria are adult patients, with established CD with ileal and / or colonic involvement, without significant clinical activity for more than 3 consecutive months with, at baseline, CDAI \<150 and CRP \<5 mg / l and faecal calprotectin \<250 μg / g, stable maintenance treatment for more than 3 months, an ileocolonoscopy planned for CD and the decision to maintain or decrease the treatment (but not increase) after the colonoscopy. All maintenance treatments are authorized / immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), biologic (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, vedolizumab) and JAK inhibitors.The main exclusion criteria are an incomplete record of the ileocolonoscopy or more than three resected ileocolonic segments (not counting ileocecal valve), taking NSAIDs in the two weeks prior to endoscopy, anoperineal MC without luminal involvement, suspicion of intestinal infection within 4 weeks prior to baseline endoscopic assessment. The expected period of recruitment is 12 months from the first patient included in the study and 20 patients will be included in each of the 16 centres in Belgium and France. At inclusion, demographic, phenotypic, medical history and treatment data will be collected and ileocolonoscopy will be performed and recorded by the local investigator using pre-specified standards, provided sufficient quality. Biological (albumin, haemoglobin, platelets, CRP and faecal calprotectin) assessments will be carried out at the inclusion and at each follow-up visit (week 26, 52 104 and unplanned). The clinical activity will be evaluated through CDAI. Within each centre, the local investigator, as local reader, will read the 20 ileocolonoscopy videos of the centre. In addition, each video will be read by central readers, selected among 12 central readers in four groups of 3 central readers. Each video will be read by 2 central readers and by a third one in case of disagreement between the first two. Each central reader will read a little more than 54 videos due to these disagreements. All these readers, local and central, will have undergone the training session validated by an examination on the evaluation of endoscopic remission. In a separate delayed session, the central readers will evaluate components of usual endoscopic severity indices. Agreement between data provided by local readers and central readers will be assessed through Kappa and intraclass correlation coefficient estimates. If agreement is satisfactory, endoscopic data provided by local readers will be used to investigate the association between baseline endoscopic evaluation and sustained clinical remission at week 104 using the logistic regression method, ROC curves, sensitivity and specificity. If agreement is poor, the association will be studied on central reader data using the same methods.
This study should provide a tool to evaluate the ability of endoscopic remission evaluation in patients in clinical remission to accurately predict sustained clinical remission. If it is the case, this tool could become the therapeutic objective for patients in clinical remission with ileal and/or colonic CD. If agreement is satisfactory between local and central reading, the tool could be used in therapeutic trials, but also in clinical practice. If this is not the case, the tool should be used in clinical trials using central readings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
CD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clinical remission CD
Group Type
OTHER
Colonoscopy
Intervention Type
DIAGNOSTIC_TEST
Colonoscopy for CD patients in clinical remission
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colonoscopy
Colonoscopy for CD patients in clinical remission
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. ≥18 year of age
2. Established CD for more than 6 months with histopathological confirmation available in the medical records of the patient
3. Clinical remission as considered by the investigators global assessment ≥3 consecutive months
4. Clinical remission at baseline (CDAI \<150) and CRP \<5 mg/l and fecal calprotectin \<250 μg/g
5. CD maintenance treatment needs to be stable for ≥3 months before baseline
6. Planned ileocolonoscopy for CD
7. Permitted maintenance treatment for CD: immunomodulators (Azathioprine, 6-mercaptopurine, methotrexate), biologicals (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, vedolizumab) and JAK inhibitors
8. No planned escalation of treatment after baseline endoscopy
9. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures
2. Established CD for more than 6 months with histopathological confirmation available in the medical records of the patient
3. Clinical remission as considered by the investigators global assessment ≥3 consecutive months
4. Clinical remission at baseline (CDAI \<150) and CRP \<5 mg/l and fecal calprotectin \<250 μg/g
5. CD maintenance treatment needs to be stable for ≥3 months before baseline
6. Planned ileocolonoscopy for CD
7. Permitted maintenance treatment for CD: immunomodulators (Azathioprine, 6-mercaptopurine, methotrexate), biologicals (infliximab, adalimumab, certolizumab, golimumab, ustekinumab, vedolizumab) and JAK inhibitors
8. No planned escalation of treatment after baseline endoscopy
9. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures
Exclusion Criteria
1. Pregnancy at time of endoscopy
2. People unable to give their consent (because of their physical or mental state).
3. Absence of written consent.
4. Ulcerative colitis or IBD type unclassified
5. Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy
6. Incomplete recording of the endoscopy or more than three resected ileocolonic segments (not counting ileocecal valve)
7. Non-steroidal anti-inflammatory drugs intake within two weeks before baseline endoscopy
8. Perianal fistulizing CD without luminal disease
9. Contraindication for endoscopy
10. Inaccessible ileocolonic segment even after attempt of endoscopic balloon dilation
11. Suspicion of gastrointestinal infection within 4 weeks prior to baseline endoscopy
12. Documented active or suspicion of intestinal tuberculosis
13. Conditions which in the opinion of the investigator may interfere with the subject's ability to comply to the follow up with the study procedures.
CREDO2-GT2017002 Getaid\_CREDO2-Protocol\_v1.1\_20171130 Page 18 of 37
14. Exclusive CD of the upper gastrointestinal tract (Montreal classification L4)
15. Montreal classification L1 without terminal ileal involvement
16. Colon preparation with solutions other than PEG or picosulphate solutions
17. Incomplete recording of the baseline endoscopy.
2. People unable to give their consent (because of their physical or mental state).
3. Absence of written consent.
4. Ulcerative colitis or IBD type unclassified
5. Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy
6. Incomplete recording of the endoscopy or more than three resected ileocolonic segments (not counting ileocecal valve)
7. Non-steroidal anti-inflammatory drugs intake within two weeks before baseline endoscopy
8. Perianal fistulizing CD without luminal disease
9. Contraindication for endoscopy
10. Inaccessible ileocolonic segment even after attempt of endoscopic balloon dilation
11. Suspicion of gastrointestinal infection within 4 weeks prior to baseline endoscopy
12. Documented active or suspicion of intestinal tuberculosis
13. Conditions which in the opinion of the investigator may interfere with the subject's ability to comply to the follow up with the study procedures.
CREDO2-GT2017002 Getaid\_CREDO2-Protocol\_v1.1\_20171130 Page 18 of 37
14. Exclusive CD of the upper gastrointestinal tract (Montreal classification L4)
15. Montreal classification L1 without terminal ileal involvement
16. Colon preparation with solutions other than PEG or picosulphate solutions
17. Incomplete recording of the baseline endoscopy.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Sponsor Role
collaborator
Biogen
INDUSTRY
Sponsor Role
collaborator
Celgene
INDUSTRY
Sponsor Role
collaborator
Gilead Sciences
INDUSTRY
Sponsor Role
collaborator
Roche Pharma AG
INDUSTRY
Sponsor Role
collaborator
Takeda
INDUSTRY
Sponsor Role
collaborator
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ Sint Lucas Gent
Ghent, , Belgium
Site Status
Leuven University Hospital
Leuven, , Belgium
Site Status
UZ Leuven
Leuven, , Belgium
Site Status
CHU Liège
Liège, , Belgium
Site Status
CHU Besançon - Hôpital Jean Minjoz
Besançon, , France
Site Status
CHU Estaing - Clermont Ferrand
Clermont-Ferrand, , France
Site Status
APHP- Hopital BEAUJON
Clichy, , France
Site Status
CHRU de Lille - Hôpital C. Huriez
Lille, , France
Site Status
CHU Montpellier - Hôpital Saint Eloi
Montpellier, , France
Site Status
CHU Nancy - Hôpital Barbois
Nancy, , France
Site Status
CHU Nantes - Hôtel Dieu
Nantes, , France
Site Status
CHU de Nice - Hôpital de l'Archet 2
Nice, , France
Site Status
Hôpital Saint Antoine
Paris, , France
Site Status
CHU Bordeaux - Hôpital Haut Lévêque
Pessac, , France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Belgium
France
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-003345-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GETAID 2017-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study
NCT02867540
UNKNOWN
NA
Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study
NCT07093294
RECRUITING
Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis
NCT02549976
COMPLETED
NA
Reliability of IUS in Crohn's Disease
NCT06833450
RECRUITING
NA
Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease
NCT06299631
COMPLETED
Response Assessment in SB CD
NCT03646708
RECRUITING
TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)
NCT05903066
RECRUITING
Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases
NCT02878395
UNKNOWN
A Comparative Study of MRI, US and CE for Assessing Treatment Response in Known Crohn's Disease
NCT03435016
COMPLETED
NA
Validation of an IUS Activity Index
NCT05407350
UNKNOWN
Feasibility of a Minimally Invasive Diagnostic Algorithm in Suspected Crohn's Disease
NCT06882993
RECRUITING
NA
The CURE - CD Trial
NCT03555058
COMPLETED
NA
Endoscopic Detection of Dysplasia in Crohn 's Disease Patient
NCT01180452
COMPLETED
PHASE4
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
NCT03458195
RECRUITING
NA
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
NCT03668249
COMPLETED
Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy
NCT00492791
COMPLETED
Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease
NCT02504255
COMPLETED
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
NCT06023030
RECRUITING
DWI MR-enterography Without or With Bowel Cleansing to Assess Intestinal Inflammatory Activity in the Follow-up of Crohn's Disease
NCT05354609
ACTIVE_NOT_RECRUITING
NA
Evaluation of the Efficacy and Safety of Endoscopic Dilatation and Biological Therapy in Intestinal Stenosis Due to CD
NCT06603298
ACTIVE_NOT_RECRUITING
Can CT Enteroclysis Predict the Outcome of Crohn's Disease
NCT00572780
COMPLETED
The CROCO Study: CROhn's Disease COhort Study
NCT05420233
RECRUITING
NA
IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
NCT06573944
RECRUITING
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
NCT04997733
RECRUITING
PHASE3